



March 21, 2022

BSE Limited

Phiroze Jeejeebhoy Towers,
Dalal Street, Mumbai – 400 001
Scrip code: 532531

The National Stock Exchange of India Limited

Exchange Plaza, Bandra-Kurla Complex
Bandra (E) Mumbai - 400 051
Scrip code: STAR

Dear Madam/ Sir,

Sub: Press Release

Please find attached Press Release issued by the Company titled:

“Strides partners with Medicines Patent Pool (MPP) to commercialize the generic version of Pfizer’s COVID-19 Oral Treatment across 95 markets”

Thanks & Regards,

For **Strides Pharma Science Limited**,

A handwritten signature in blue ink that reads 'Manjula R.'.

Manjula Ramamurthy
Company Secretary



Encl. As above

Strides Pharma Science Limited

CIN: L24230MH1990PLC057062

Corp Off: Strides House, Bilekahalli, Bannerghatta Road, Bengaluru - 560 076, India | Tel: +91 80 6784 0000 Fax: +91 80 6784 0700
Regd Off: 201, Devavrata, Sector 17, Vashi, Navi Mumbai – 400 703, India | Tel: +91 22 2789 2924 / 3199 Fax: +91 22 2789 2942

corpcomm@strides.com, www.strides.com



Strides partners with Medicines Patent Pool (MPP) to commercialize the generic version of Pfizer's COVID-19 Oral Treatment across 95 markets

- *Branded as Kovidax, Strides' generic version of Pfizer's COVID-19 oral treatment is developed for the Global markets with a vertically integrated supply chain*
- *Pfizer's Covid-19 oral treatment has received USFDA Emergency Use Authorization (EUA) for COVID-19 Oral Antiviral Treatment.*

Bengaluru, March 21, 2022: Strides Pharma Science Limited (BSE: 532531, NSE: STAR, Company or Strides), a global pharmaceutical company, today announced a sub-license agreement with MPP to commercialize a generic version of Pfizer's COVID-19 oral treatment in 95 low and middle-income markets.

Developed by Pfizer, the treatment is a SARS-CoV-2 main protease inhibitor oral antiviral therapy. The drug consists of nirmatrelvir tablets which are co-packaged and co-administered with ritonavir tablets. The product has been authorized as a Covid-19 oral therapy for emergency use in the U.S. and many other countries, both amongst high-risk adults and high-risk pediatric patients.

Branded as Kovidax, Strides' generic version of the Pfizer oral treatment will be launched in 95 markets as part of the sub-licensing agreement with MPP. The product will be manufactured at Strides' flagship facility in Bengaluru, and the Company has already secured its Active Pharmaceutical Ingredients (API) supplies through a preferred partnership arrangement.

Arun Kumar, Founder, Strides Pharma Science Limited said, *"Kovidax is the latest addition to our covid care portfolio and is part of our commitment to produce high-quality medicines to fight the challenges of Covid-19 outbreak around the world. We are glad to collaborate with MPP to commercialize the generic version of the Pfizer product and reach out to the global markets. Our forte lies in the scalability and affordability, and we are hopeful of maximizing the reach for Kovidax in a short period."*

The Pfizer COVID-19 oral treatment has shown to have reduced the risk of hospitalization or death for any cause by 89% within three days of symptom onset compared to placebo. It is administered as a dose of 300 mg of nirmatrelvir with 100 mg tablet of ritonavir, given twice daily for five days. The FDA's emergency use authorization for the oral treatment is based on the clinical data from the Phase 2/3 EPIC-HR (Evaluation of Protease Inhibition for COVID-19 in High-Risk Patients) trial conducted by Pfizer.

About Strides

Strides, listed on the BSE Limited (532531) and National Stock Exchange of India Limited (STAR), is a global pharmaceutical company headquartered in Bengaluru, India. The Company mainly operates in the regulated markets and has an "in Africa for Africa" strategy and an institutional business to service donor-funded markets. The Company's global manufacturing sites are located in India (Chennai, Puducherry and two locations in Bengaluru), Singapore, Italy (Milan), Kenya (Nairobi), and the United States (New York). The Company focuses on "difficult to manufacture" products sold in over 100 countries. Additional information is available at the Company's website at www.strides.com

For further information, please contact

<p>Strides Badree Komandur Executive Director – Finance & Group CFO +91 80 6784 0747</p> <p>Investor Relations: Sandeep Baid: +91 80 6784 0791 sandeep.baid@strides.com</p>	<p>Corporate Communication Pallavi Panchmatia: +91 80 6784 0193 pallavi.panchmatia@strides.com</p> <p>PR Consultancy Boni Mukherjee: +91 9618682208 boni@fortunapr.com</p>
---	---



Strides Pharma Science Limited

CIN: L24230MH1990PLC057062

Regd. Office: 201, 'Devavrata', Sector - 17, Vashi,
Navi Mumbai - 400 703

Corp. Office: Strides House, Bannerghatta Road,
Bengaluru – 560076

Fortuna PR

K Srinivas Reddy: +91 90005 27213

srinivas@fortunapr.com